Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink ...

Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative ...

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

In a challenging market environment, TNGX stock has reached a new 52-week low, with shares plummeting to $2.58. According to InvestingPro data, while the company maintains strong liquidity with a ...

Looking at Tango Therapeutics, Inc.'s ( NASDAQ:TNGX ) insider transactions over the last year, we can see that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

BOSTON—Barbara Weber, the Chief Executive Officer of Tango Therapeutics, Inc. (NASDAQ:TNGX), a $350 million market cap biotech company, recently sold a portion of her holdings in the company.